Abbott latest victim of FDA’s missed PDUFA dates
Abbott Laboratories joins the ranks of pharma companies whose PDUFA action dates for NDAs have passed, as FDA told the company this week it needs more time to review its cholesterol drug TriLipix (ABT-335), a next-generation fenofibrate. The agency did not request additional data or extend the drug's PDUFA date. Abbott joins a long list of drug companies affected by the resource-strapped agency (1"The Pink Sheet," Sept. 29, 2008, p. 21). Abbott still expects a fourth quarter approval. It was a rough week for Abbott, as the company also received a complete response letter Oct. 20 from FDA for its NDA for a controlled-release form of hydrocodone with acetaminophen
You may also be interested in...
FDA's ability to meet its Prescription Drug User Fee Act deadlines for new product approvals may end up below the agency's earlier estimates, according to Office of New Drugs Director John Jenkins
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.
In an interview, OND Deputy Director of Operations Kevin Bugin describes how FDA might be able to "accelerate" the transition back to in-person meetings if the initial phase with Type A and BPD Type 1 meetings goes well. But there is still no plan to return to in-person advisory committees.